Výsledky vyhledávání - "Ellen K. Ritchie"

Akademický článek

Treatment comparison of hydroxyurea versus ruxolitinib in essential thrombocythaemia: A matched‐cohort analysis

Autor: Michael R. Grunwald, Ellen K. Ritchie, Elisa Rumi, Albert Assad, J. E. Hamer‐Maansson, Jingbo Yu, Tricia Kalafut, Evan Braunstein, Francesco Passamonti

Publikováno v: eJHaem, Vol 5, Iss 4, Pp 778-783 (2024)

Abstract Hydroxyurea is the preferred first‐line cytoreductive treatment for high‐risk essential thrombocythaemia (ET), but many patients are intolerant or refractory to hydroxyurea. Ruxolitinib has been shown to improve symptoms in patients with

Externí odkaz: https://doaj.org/article/6bdb75eeb74c4a4e830c97716856dfc8

Zobrazit plný text záznamu

Akademický článek

Comparison of Multiple Clinical Testing Modalities for Assessment of NPM1-Mutant AML

Autor: Amanda Lopez, Sanjay Patel, Julia T. Geyer, Joelle Racchumi, Amy Chadburn, Paul Simonson, Madhu M. Ouseph, Giorgio Inghirami, Nuria Mencia-Trinchant, Monica L. Guzman, Alexandra Gomez-Arteaga, Sangmin Lee, Pinkal Desai, Ellen K. Ritchie, Gail J. Roboz, Wayne Tam, Michael J. Kluk

Publikováno v: Frontiers in Oncology, Vol 11 (2021)

BackgroundNPM1 mutation status can influence prognosis and management in AML. Accordingly, clinical testing (i.e., RT-PCR, NGS and IHC) for mutant NPM1 is increasing in order to detect residual disease in AML, alongside flow cytometry (FC). However,

Externí odkaz: https://doaj.org/article/f8a72db61b544a4bb1c2cd20d3ec0754

Zobrazit plný text záznamu

Akademický článek

Pediatric-inspired chemotherapy incorporating pegaspargase is safe and results in high rates of minimal residual disease negativity in adults up to age 60 with Philadelphia chromosome-negative acute lymphoblastic leukemia

Autor: Mark B. Geyer, Ellen K. Ritchie, Arati V. Rao, Shreya Vemuri, Jessica Flynn, Meier Hsu, Sean M. Devlin, Mikhail Roshal, Qi Gao, Madhulika Shukla, Jose M. Salcedo, Peter Maslak, Martin S. Tallman, Dan Douer, Jae H. Park

Publikováno v: Haematologica, Vol 106, Iss 8 (2020)

Administration of pediatric-inspired chemotherapy to adults up to age 60 with acute lymphoblastic leukemia (ALL) is challenging in part due to toxicities of asparaginase as well as myelosuppression. We conducted a multicenter phase II clinical trial

Externí odkaz: https://doaj.org/article/5b2e995adcfa4bf8893807d57ad1b9bd

Zobrazit plný text záznamu

Akademický článek

The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort

Publikováno v: Blood Advances, Vol 2, Iss 14, Pp 1765-1772 (2018)

Abstract: Most studies of immunosuppressive therapy (IST) in myelodysplastic syndromes (MDS) are limited by small numbers and their single-center nature, and report conflicting data regarding predictors for response to IST. We examined outcomes assoc

Externí odkaz: https://doaj.org/article/a5a59ecccd024d588117d21e7d6e571f

Zobrazit plný text záznamu

Akademický článek

Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort

Publikováno v: Blood Advances, Vol 2, Iss 8, Pp 923-932 (2018)

Abstract: Although hypomethylating agents (HMAs) are frequently used in the frontline treatment of older acute myeloid leukemia (AML) patients, little is known about their effectiveness in relapsed or primary treatment–refractory (RR)-AML. Using an

Externí odkaz: https://doaj.org/article/486ed8a5f054402fbec21f16b3f0cd0a

Zobrazit plný text záznamu

Akademický článek

Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemia

Publikováno v: BMC Cancer, Vol 18, Iss 1, Pp 1-8 (2018)

Abstract Background Treatment of chronic myeloid leukemia with a tyrosine kinase inhibitor (TKI) offers significant improvements over previous treatments in terms of survival and toxicity yet nevertheless is associated with reduced health-related qua

Externí odkaz: https://doaj.org/article/743a6fad3b1d4b809b6fa2c4648fed97

Zobrazit plný text záznamu

Akademický článek

Phase 3 results for vosaroxin/cytarabine in the subset of patients ≥60 years old with refractory/early relapsed acute myeloid leukemia

Publikováno v: Haematologica, Vol 103, Iss 11 (2018)

Externí odkaz: https://doaj.org/article/5384cf102cb7445faf426cdc5236f71f

Zobrazit plný text záznamu

Akademický článek

Phase I trial of plerixafor combined with decitabine in newly diagnosed older patients with acute myeloid leukemia

Autor: Gail J. Roboz, Ellen K. Ritchie, Yulia Dault, Linda Lam, Danielle C. Marshall, Nicole M. Cruz, Hsiao-Ting C. Hsu, Duane C. Hassane, Paul J. Christos, Cindy Ippoliti, Joseph M. Scandura, Monica L. Guzman

Publikováno v: Haematologica, Vol 103, Iss 8 (2018)

Acute myeloid leukemia carries a dismal prognosis in older patients. The objective of this study was to investigate the safety and efficacy of decitabine combined with the CXCR4 antagonist plerixafor in newly diagnosed older patients with acute myelo

Externí odkaz: https://doaj.org/article/373fb383089440989a2d3b9efeec3de1

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání